A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In
Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market
High cholesterol has long been a silent threat lurking in
Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan.
For decades, the United States has led the world in
A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
CRISPR-Cas9 Enhances Rice Yields Without Introducing Foreign DNA
This study explores the use of CRISPR-Cas9 technology to increase
MOST POPULAR
